Trial Profile
A Phase II Open-Label, Randomized Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients with Lung Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; L-DOS 47 (Primary) ; Vinorelbine (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Sponsors Helix BioPharma
- 23 Aug 2021 Status changed from suspended to discontinued.
- 09 Feb 2021 Status changed from recruiting to suspended. Reason the study was stopped:Study was halted at this time due to other budgetary priorities.
- 02 Apr 2020 According to a Helix BioPharma media release, the locations Poland and Ukraine in this study no longer requires patient enrollment.